European connection in Demark tells me there is a suitor for Nycomed. Mackinsey and Goldman doing alot of due-dill. Expecting buy by Q2/Q3 2011. Any one know more about this?
Thanks.
Thanks.
Who is considering the buy of Nycomed?
- Thread starter Anonymous
- Start date
-
- Tags
- None
Nyconed was sold to Satan a long time ago. He's doing a good job running the company into the ground and staight to hell.
about 10B Euros. Access to EGMs is the value, especially China where Nycomed is has its key growth strategy planted, and Russia CIS too. LATAM showing some signs of growth, but APAC will lead the way. The buyer will be one looking to either access EGM or Western EU markets, they will have limited global presence, but we'll find out soon.
Perrigo or Teva? none of both. try again or wait another few days...
i heard that they are they right now far above the due-dill phase. buyer name is already known. guess who?
Costello!!!
But seriously, that sounds interesting to me. They don't make any of the product we do so there would be the possibility they may buy us to keep.
Plus they have a place in NJ and on in MA in addition to some others so NY would be nice.
I really know nothing of these things, but it's nice to think positive.
I have heard that the buyer is Takeda Pharamceuticals of Japan
the buyer is Takeda Pharamceuticals - i have the same information, it's not just a rumour
Well it's a rumor until it's a confirmed fact, which it is not.
Either way, that doesn't sound so bad. Takeda does not have a topicals division that I can see so our product line would be new to them.
Could be a good thing.
Takeda takeover seems to be a fact, due to information from Zuerich HQ.
That last sentence makes it fact.
The exclamation point means it is real.
3 exclamation points! Ok, this has to be real!
Another thread that highlights that nothing on this board is fact. It screams BS.
Well, currently Sanofi is offering its dermatology business, that would fit also to Nycomed - offering growth potential - therefore also PE groups could be interested.
Finally, someone that sees the cup as half full instead of half empty. If you examine the fundamentals of our company and the dermatology space, we are more likely to acquire than be acquired.